ARIX BIOSCIENCE PLC Unaudited NAV for May 2022

Directive transparence : information réglementée

09/06/2022 08:00

Arix Bioscience PLC (ARIX)
Unaudited NAV for May 2022

09-Jun-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc


Unaudited NAV for May 2022


LONDON, 9 June 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited NAV of the Company for date ended 31 May 2022 as follows:




NAV Breakdown

Total NAV


NAV per share

Listed Portfolio

Unlisted Portfolio


Other Interests
















For more information on Arix, please contact:


Arix Bioscience plc

+44 (0)20 7290 1050



Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446



About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.


We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com



ISIN: GB00BD045071
Category Code: NAV
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 167035
EQS News ID: 1371457

End of Announcement EQS News Service


15/09/2022 08:00
12/08/2022 08:00
10/08/2022 19:05
10/08/2022 18:46
10/08/2022 08:01
10/08/2022 08:00
03/08/2022 08:00
22/07/2022 08:00
22/06/2022 17:45
22/06/2022 08:00